AstraZeneca plc 11.5% Potential Upside Indicated by Barclays Capital

Broker Ratings

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 8000 GBX on its stock. This is indicating the analyst believes there is a potential upside of 11.5% from the opening price of 7174 GBX. Over the last 30 and 90 trading days the company share price has increased 52 points and increased 1113 points respectively. The 52 week high share price is 7583 GBX while the 52 week low for the stock is 5312 GBX.

AstraZeneca plc has a 50 day moving average of 7,001.80 GBX and a 200 day moving average of 6,293.44. There are currently 1,311,882,856 shares in issue with the average daily volume traded being 2,217,050. Market capitalisation for LON:AZN is £94,888,486,974 GBP.

Share on:
Find more news, interviews, share price & company profile here for:
    AstraZeneca and Daiichi Sankyo's Datroway gains FDA approval, offering a new treatment option for specific metastatic breast cancer cases.
    AstraZeneca's Tagrisso gains EU approval for treating advanced NSCLC, showing significant efficacy in reducing disease progression in key trials.
    AstraZeneca's Imfinzi receives FDA approval for limited-stage small cell lung cancer, marking a significant breakthrough in extending patient survival.

      Search

      Search